First- and second-line therapy of metastatic colorectal cancer

Shelby Terstriep, Axel F Grothey

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer. In 2006, 148,610 colorectal cancer cases are expected in the USA, with 55,170 deaths expected from this disease. After years of stagnation, the treatment of metastatic colorectal cancer has recently made dramatic advances. The previous standard of care, 5-fluorouracil, is the now the backbone of combination regimens with oxaliplatin or irinotecan. The addition of biological agents, such as the vascular endothelial growth factor inhibitor, bevacizumab, and the epidermal growth factor receptor inhibitors, cetuximab and panitumumab, have further enhanced the activity of conventional chemotherapy. These advances have increased the overall survival of advanced colorectal cancer patients, which was once 6 months with best supportive care, to over 2 years if all active agents are used in the course of the disease.

Original languageEnglish (US)
Pages (from-to)921-930
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume6
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Colorectal Neoplasms
irinotecan
oxaliplatin
Second Primary Neoplasms
Biological Factors
Therapeutics
Standard of Care
Epidermal Growth Factor Receptor
Fluorouracil
Vascular Endothelial Growth Factor A
Cause of Death
Lung Neoplasms
Drug Therapy
Survival
Neoplasms

Keywords

  • Bevacizumab
  • Chemotherapy
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

First- and second-line therapy of metastatic colorectal cancer. / Terstriep, Shelby; Grothey, Axel F.

In: Expert Review of Anticancer Therapy, Vol. 6, No. 6, 06.2006, p. 921-930.

Research output: Contribution to journalArticle

Terstriep, Shelby ; Grothey, Axel F. / First- and second-line therapy of metastatic colorectal cancer. In: Expert Review of Anticancer Therapy. 2006 ; Vol. 6, No. 6. pp. 921-930.
@article{93c81414ca7c4db286f94fd296543f55,
title = "First- and second-line therapy of metastatic colorectal cancer",
abstract = "In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer. In 2006, 148,610 colorectal cancer cases are expected in the USA, with 55,170 deaths expected from this disease. After years of stagnation, the treatment of metastatic colorectal cancer has recently made dramatic advances. The previous standard of care, 5-fluorouracil, is the now the backbone of combination regimens with oxaliplatin or irinotecan. The addition of biological agents, such as the vascular endothelial growth factor inhibitor, bevacizumab, and the epidermal growth factor receptor inhibitors, cetuximab and panitumumab, have further enhanced the activity of conventional chemotherapy. These advances have increased the overall survival of advanced colorectal cancer patients, which was once 6 months with best supportive care, to over 2 years if all active agents are used in the course of the disease.",
keywords = "Bevacizumab, Chemotherapy, Colorectal cancer, Irinotecan, Oxaliplatin",
author = "Shelby Terstriep and Grothey, {Axel F}",
year = "2006",
month = "6",
doi = "10.1586/14737140.6.6.921",
language = "English (US)",
volume = "6",
pages = "921--930",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - First- and second-line therapy of metastatic colorectal cancer

AU - Terstriep, Shelby

AU - Grothey, Axel F

PY - 2006/6

Y1 - 2006/6

N2 - In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer. In 2006, 148,610 colorectal cancer cases are expected in the USA, with 55,170 deaths expected from this disease. After years of stagnation, the treatment of metastatic colorectal cancer has recently made dramatic advances. The previous standard of care, 5-fluorouracil, is the now the backbone of combination regimens with oxaliplatin or irinotecan. The addition of biological agents, such as the vascular endothelial growth factor inhibitor, bevacizumab, and the epidermal growth factor receptor inhibitors, cetuximab and panitumumab, have further enhanced the activity of conventional chemotherapy. These advances have increased the overall survival of advanced colorectal cancer patients, which was once 6 months with best supportive care, to over 2 years if all active agents are used in the course of the disease.

AB - In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer. In 2006, 148,610 colorectal cancer cases are expected in the USA, with 55,170 deaths expected from this disease. After years of stagnation, the treatment of metastatic colorectal cancer has recently made dramatic advances. The previous standard of care, 5-fluorouracil, is the now the backbone of combination regimens with oxaliplatin or irinotecan. The addition of biological agents, such as the vascular endothelial growth factor inhibitor, bevacizumab, and the epidermal growth factor receptor inhibitors, cetuximab and panitumumab, have further enhanced the activity of conventional chemotherapy. These advances have increased the overall survival of advanced colorectal cancer patients, which was once 6 months with best supportive care, to over 2 years if all active agents are used in the course of the disease.

KW - Bevacizumab

KW - Chemotherapy

KW - Colorectal cancer

KW - Irinotecan

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=33745131818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745131818&partnerID=8YFLogxK

U2 - 10.1586/14737140.6.6.921

DO - 10.1586/14737140.6.6.921

M3 - Article

C2 - 16761936

AN - SCOPUS:33745131818

VL - 6

SP - 921

EP - 930

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -